Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387881 · ClinicalTrials.gov registry record · Phase 3
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 679
- Enrollment target
NCT00387881 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 679 participants.
The verdict
NCT00387881, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 679 participants
- Enrollment target
Study Summary
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
Interventions
- DRUG Placebo
- DRUG sumatriptan succinate / naproxen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 679 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387881
The ClinicalTrials.gov registry entry for NCT00387881 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 679 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00387881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387881 about?
NCT00387881 is a clinical study titled "TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)". This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
What is the current status of trial NCT00387881?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 679 participants. The study started on 2006-09. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00387881?
The interventions under investigation include: Placebo (DRUG), sumatriptan succinate / naproxen sodium (DRUG).
Who is sponsoring clinical trial NCT00387881?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.